AR107295A1 - Administración intradérmica de una composición de inmunoglobulina g - Google Patents
Administración intradérmica de una composición de inmunoglobulina gInfo
- Publication number
- AR107295A1 AR107295A1 ARP170100019A ARP170100019A AR107295A1 AR 107295 A1 AR107295 A1 AR 107295A1 AR P170100019 A ARP170100019 A AR P170100019A AR P170100019 A ARP170100019 A AR P170100019A AR 107295 A1 AR107295 A1 AR 107295A1
- Authority
- AR
- Argentina
- Prior art keywords
- igg
- composition
- immunodeficiency
- administration
- subject
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 9
- 206010061598 Immunodeficiency Diseases 0.000 abstract 3
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 3
- 230000007813 immunodeficiency Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 abstract 1
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 208000031951 Primary immunodeficiency Diseases 0.000 abstract 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 abstract 1
- 231100000223 dermal penetration Toxicity 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Un procedimiento para la administración de una preparación de IgG por vía intradérmica (ID) a un sujeto con necesidad de la misma incluye la carga con un volumen de la preparación de IgG a un dispositivo de administración ID que incluye agujas, la aplicación del dispositivo a un sitio de administración en la piel, la utilización del dispositivo para permitir la penetración dérmica de las agujas, la administración del volumen de la preparación de IgG en el sitio de administración en la piel y la retirada del dispositivo de administración de la inyección. Las composiciones de una preparación de IgG son para la utilización en el tratamiento de una enfermedad en un sujeto con necesidad de las mismas mediante el procedimiento mencionado anteriormente. La enfermedad puede ser una inmunodeficiencia. Reivindicación 1: Composición que comprende IgG para la utilización en el tratamiento de una inmunodeficiencia en un sujeto con necesidad del mismo por una vía intradérmica (ID) mediante la utilización de un dispositivo ID que se puede retirar que comprende agujas. Reivindicación 2: Composición para la utilización, según la reivindicación 1, en la que la composición de IgG tiene una concentración de IgG del 15% al 30% (p/v). Reivindicación 4: Composición para la utilización, según la reivindicación 1, en la que un pH de la composición de IgG es de 4,5 a 8,0. Reivindicación 9: Composición para la utilización, según la reivindicación 1, en la que la composición de IgG comprende una o más proteínas plasmáticas adicionales. Reivindicación 20: Composición, según la reivindicación 19, en la que la inmunodeficiencia es una de una inmunodeficiencia primaria, una inmunodeficiencia secundaria o una inmunodeficiencia adquirida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292075P | 2016-02-05 | 2016-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107295A1 true AR107295A1 (es) | 2018-04-18 |
Family
ID=57944251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100019A AR107295A1 (es) | 2016-02-05 | 2017-01-05 | Administración intradérmica de una composición de inmunoglobulina g |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20170226191A1 (es) |
| EP (1) | EP3202393B1 (es) |
| JP (1) | JP7033848B2 (es) |
| KR (1) | KR20170093704A (es) |
| CN (1) | CN107041953A (es) |
| AR (1) | AR107295A1 (es) |
| AU (1) | AU2017200007B2 (es) |
| CA (1) | CA2953543A1 (es) |
| CL (1) | CL2017000016A1 (es) |
| ES (1) | ES2929631T3 (es) |
| IL (1) | IL249795B (es) |
| MX (1) | MX2017000268A (es) |
| MY (1) | MY198746A (es) |
| PL (1) | PL3202393T3 (es) |
| RU (1) | RU2762499C2 (es) |
| SG (1) | SG10201700022QA (es) |
| TW (1) | TWI791425B (es) |
| UY (1) | UY37061A (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7025144B2 (ja) * | 2017-07-13 | 2022-02-24 | 株式会社メガチップス | 電子メロディ特定装置、プログラム、及び電子メロディ特定方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20050180952A1 (en) * | 2003-08-26 | 2005-08-18 | Pettis Ronald J. | Methods for intradermal delivery of therapeutics agents |
| WO2005086773A2 (en) * | 2004-03-08 | 2005-09-22 | Becton Dickinson And Company | A method for delivering therapeutic proteins to the intradermal compartment |
| CN103897063B (zh) | 2007-06-01 | 2017-04-12 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| TWI532498B (zh) * | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| EP2704751B1 (en) | 2011-05-02 | 2019-04-17 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| CN105025925A (zh) * | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | 抗-催乳素受体抗体制剂 |
| WO2016161423A1 (en) | 2015-04-02 | 2016-10-06 | Kieu Hoang | Process of cloning and further purification to make a recombinant intravenous immunoglobulin |
-
2016
- 2016-12-27 IL IL249795A patent/IL249795B/en active IP Right Grant
-
2017
- 2017-01-02 UY UY0001037061A patent/UY37061A/es not_active Application Discontinuation
- 2017-01-03 AU AU2017200007A patent/AU2017200007B2/en active Active
- 2017-01-03 EP EP17150114.1A patent/EP3202393B1/en active Active
- 2017-01-03 SG SG10201700022QA patent/SG10201700022QA/en unknown
- 2017-01-03 MY MYPI2017700009A patent/MY198746A/en unknown
- 2017-01-03 PL PL17150114.1T patent/PL3202393T3/pl unknown
- 2017-01-03 ES ES17150114T patent/ES2929631T3/es active Active
- 2017-01-03 CA CA2953543A patent/CA2953543A1/en active Pending
- 2017-01-05 AR ARP170100019A patent/AR107295A1/es unknown
- 2017-01-05 CL CL2017000016A patent/CL2017000016A1/es unknown
- 2017-01-05 MX MX2017000268A patent/MX2017000268A/es unknown
- 2017-01-11 CN CN201710018106.8A patent/CN107041953A/zh active Pending
- 2017-01-12 JP JP2017003151A patent/JP7033848B2/ja active Active
- 2017-01-12 KR KR1020170004993A patent/KR20170093704A/ko not_active Application Discontinuation
- 2017-01-12 RU RU2017100665A patent/RU2762499C2/ru active
- 2017-01-16 US US15/407,139 patent/US20170226191A1/en not_active Abandoned
- 2017-01-16 TW TW106101375A patent/TWI791425B/zh active
-
2020
- 2020-02-28 US US16/805,425 patent/US12091444B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL249795B (en) | 2020-01-30 |
| KR20170093704A (ko) | 2017-08-16 |
| MX2017000268A (es) | 2018-07-04 |
| IL249795A0 (en) | 2017-03-30 |
| CA2953543A1 (en) | 2017-08-05 |
| JP7033848B2 (ja) | 2022-03-11 |
| MY198746A (en) | 2023-09-22 |
| UY37061A (es) | 2017-03-31 |
| EP3202393B1 (en) | 2022-08-31 |
| TW201728338A (zh) | 2017-08-16 |
| EP3202393A1 (en) | 2017-08-09 |
| RU2762499C2 (ru) | 2021-12-21 |
| JP2017137297A (ja) | 2017-08-10 |
| US12091444B2 (en) | 2024-09-17 |
| TWI791425B (zh) | 2023-02-11 |
| CN107041953A (zh) | 2017-08-15 |
| ES2929631T3 (es) | 2022-11-30 |
| AU2017200007B2 (en) | 2023-07-06 |
| PL3202393T3 (pl) | 2022-12-19 |
| AU2017200007A1 (en) | 2017-08-24 |
| US20200199201A1 (en) | 2020-06-25 |
| RU2017100665A3 (es) | 2020-05-20 |
| US20170226191A1 (en) | 2017-08-10 |
| SG10201700022QA (en) | 2017-09-28 |
| CL2017000016A1 (es) | 2017-06-16 |
| RU2017100665A (ru) | 2018-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000187A (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
| CO2019002371A2 (es) | Adenovirus armado con captador biespecífico de linfocitos t (bite) | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| PE20190910A1 (es) | Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| CY1123963T1 (el) | Καινοτομα πολυμερικα προφαρμακα hgh | |
| UY36465A (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| EA201891606A1 (ru) | Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| AR096893A1 (es) | Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
| CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
| WO2018143552A3 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
| CY1121566T1 (el) | Νευροπροστατευτικο και ενδειξη αυτου | |
| CL2018001104A1 (es) | Composición para el cuidado de la piel y procedimiento asociado. | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| PE20200600A1 (es) | Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc |